Anthropic, an AI company known for its work on large language models, has confirmed it is operating a wet biology lab in the San Francisco Bay Area where it conducts physical biology experiments using AI models. This development aligns with CEO Dario Amodei’s recent assertion that AI could potentially cure many major diseases within the next five to ten years. Eric Kauderer-Abrams, Anthropic’s head of life sciences, emphasized that despite advances in AI, real-world lab testing remains essential for biological research, and Anthropic’s lab functions similarly to a traditional biotech facility, conducting internal research alongside collaborations with external partners.

This announcement follows Anthropic’s acquisition of stealth biotech startup Coefficient Bio in April, reinforcing its strategic push into combining AI with biological sciences. While specifics on the wet lab’s projects have not been fully disclosed, officials say the focus is primarily on fundamental biology research rather than immediate drug discovery. This distinction is significant, as Anthropic maintains partnerships and deals with major pharmaceutical companies such as Novo Nordisk, highlighting the company’s intent not to compete directly with the pharma sector but rather to complement it.

In addition to the lab, Anthropic recently launched a Life Sciences Verification Program to grant qualified biological researchers access to its most advanced AI models. The company has also published research reports aimed at accelerating protein design and improving biomolecular modeling, both crucial steps in advancing drug discovery. These efforts underscore Anthropic’s positioning at the intersection of AI and biology, as it seeks to leverage computational models to push forward scientific breakthroughs while navigating industry collaboration dynamics.

Despite its optimistic vision for AI, Anthropic faces internal and external concerns regarding the risks posed by artificial intelligence. The resignation of researcher Jacob Coxon, who warned about the existential dangers of AI, and public statements from the company’s own alignment lead suggesting a non-negligible risk of human extinction within a decade, highlight increasing calls for caution. CEO Dario Amodei has echoed these concerns recently, urging the industry towards self-regulation, which creates a stark contrast with the company’s simultaneous commitment to conducting advanced biological experiments in its new wet lab.